Kant S, Bhalla A, Alasfar S, et al. - Researchers describe their 10-year experience of atypical hemolytic uremic syndrome (aHUS) management in kidney transplant recipients (KTRs), using Eculizumab therapy in the prophylaxis as well as in the treatment of the disease recurrence, via this retrospective study. This analysis involved 19 patients with aHUS who received 36 kidney transplants in total, 10 of them had 2 or more prior kidney transplants. Experts administered Eculizumab prophylaxis to 10/19 (56%) at the time of transplantation, and reported no aHUS recurrence during the follow up. Overall, findings revealed the safety as well as the effectiveness of Eculizumab prophylaxis in KTRs with aHUS. As per long term follow up, it may be likely to stop prophylaxis cautiously in selected patients with no proof of complement mutations.